INVIVYD, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.26 USD | -6.61% |
|
-6.61% | -42.64% |
| May. 09 | Transcript : Invivyd, Inc., Q1 2024 Earnings Call, May 09, 2024 | |
| May. 09 | Invivyd, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Presentation Operator MessageOperator (Operator)Welcome to the Invivyd First Quarter 2023 Fina...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Invivyd, Inc. is a commercial-stage company, which is engaged in delivering antibody-based therapies. The Companyâs proprietary INVYMAB platform approach combines state-of-the-art viral surveillance and predictive modeling with advanced antibody engineering. INVYMAB is designed to facilitate the rapid, serial generation of new monoclonal antibodies (mAbs) to keep pace with evolving viral threats. The Company delivers antibody-based therapies that protect vulnerable people from the devastating consequences of circulating viral threats, such as SARS-CoV-2 (COVID-19). Its PEMGARDA is the Companyâs first mAb in a planned series of innovative mAb candidates designed to keep pace with SARS-CoV-2 viral evolution. Its VYD2311 is optimized for neutralization potency against recent SARS-CoV-2 lineages such as BA.2.86 and JN.1. The Company also has additional anti-SARS-CoV-2 mAb candidates in discovery and pre-clinical characterization.
Calendar
2024-05-21
- Annual General Meeting
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
2.26
USD
Average target price
9.375
USD
Spread / Average Target
+314.82%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -42.64% | 269M | |
| +3.91% | 109B | |
| +10.87% | 105B | |
| +1.28% | 22.25B | |
| -13.14% | 22.09B | |
| -7.05% | 18.68B | |
| -38.36% | 17.58B | |
| -10.66% | 16.85B | |
| +3.75% | 13.76B | |
| +36.70% | 12.46B |
- Stock Market
- Equities
- IVVD Stock
- News Invivyd, Inc.
- Transcript : Invivyd, Inc., Q1 2023 Earnings Call, May 11, 2023